Sera Prognostics (SERA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with voting available online or virtually.
Shareholders are encouraged to review proxy materials and annual reports before voting.
Voting matters and shareholder proposals
Election of three directors: Jeffrey T. Elliott, Kim Kamdar, Ph.D., and Sandra A.J. Lawrence, with board recommending a vote in favor.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended by the board.
Proxy holders authorized to vote on any other business arising at the meeting.
Board of directors and corporate governance
Board slate includes three nominees for director positions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sera Prognostics
- Director elections, auditor ratification, and ESG priorities highlight this year's proxy.SERA
Proxy filing24 Apr 2026 - PRIME study validated efficacy, commercial expansion advanced, and cash runway secured.SERA
Q4 202518 Mar 2026 - PreTRM enables early, validated prediction of preterm birth, reducing NICU admissions and costs.SERA
Corporate presentation18 Mar 2026 - Strong clinical results drive rapid US expansion and set the stage for European market entry.SERA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation2 Mar 2026 - Innovative preterm birth screening test shows strong clinical and economic impact, with broad adoption targeted.SERA
H.C. Wainwright 26th Annual Global Investment Conference 20243 Feb 2026 - Net loss narrowed 21% as cash runway extends to 2027 and pivotal PreTRM studies advance.SERA
Q2 20242 Feb 2026 - Genomic and proteomic innovations are reshaping newborn care, with adoption set to accelerate.SERA
UBS Genomic Medicine Conference2 Feb 2026 - Q3 revenue fell and losses widened, but PRIME study and new initiatives aim to drive growth.SERA
Q3 202416 Jan 2026